Expert perspectives on biosimilar monoclonal antibodies in breast cancer.

ABSTRACT: While biosimilars of low molecular-weight biologics such as G-CSF have been available in Europe since 2006, biosimilars of monoclonal antibodies (mAbs) have only become available in the last year. Unlike G-CSF, mAbs are large and complex and often play a direct role in the survival of patients with life-threatening illnesses such as breast cancer. Several biosimilars are currently under development for the treatment of breast cancer, and the use of biosimilars in a setting that directly impacts patient survival raises a number of questions. In this review, we discuss the biosimilar mAbs currently in development for the treatment of breast cancer. We provide an overview of the European Medicine Agency guidelines and historic data on the development of biosimilars in order to discuss the dev

SUBMITTER: Cortes J 

PROVIDER: S-EPMC3949011 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature